The Conversation (0)
PRA Health Sciences (NASDAQ:PRAH) reported financial results for the quarter and year ended December 31, 2017. For the three months ended December 31, 2017, service revenue was $568.8 million, which represents growth of 37.5%, or $155.2 million, compared to the fourth quarter of 2016 at actual foreign exchange rates. As quoted in the press release: “We are pleased …
PRA Health Sciences (NASDAQ:PRAH) reported financial results for the quarter and year ended December 31, 2017. For the three months ended December 31, 2017, service revenue was $568.8 million, which represents growth of 37.5%, or $155.2 million, compared to the fourth quarter of 2016 at actual foreign exchange rates.
As quoted in the press release:
“We are pleased with our financial results for the quarter and are delighted to have delivered double digit constant currency revenue, adjusted earnings and new business growth,” said Colin Shannon, PRA’s Chief Executive Officer. “We believe we are well positioned for the coming year, as evidenced by our record level of new business awards and backlog, we continue to stay focused on our key strategic initiatives, and we look forward to delivering strong results in 2018.”
Latest News
Outlook Reports world
Featured Pharmaceutical Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES